TABLE 16.
Clinical and in vitro resistance to echinocandins in patients with candidiasisa
| Study | Species | Infection type | No. of isolates | Echinocandin MIC range (μg/ml)b | Coresistance |
|---|---|---|---|---|---|
| Moudgal et al. (167) | C. parapsilosis | Endocarditis | 6 | 2->16* | Caspofungin, micafungin, azoles |
| Dodgson et al. (63) | C. glabrata | Candidemia | 15 | 0.12->8* | Caspofungin, azoles |
| Krogh-Madsen et al. (120) | C. glabrata | Candidemia | 4 | 0.5->8* | Caspofungin, amphotericin B, azoles |
| Hernandez et al. (102) | C. albicans | Esophagitis | 3 | 0.25->64* | Caspofungin, azoles |
| Laverdiere et al. (126) | C. albicans | Esophagitis | 4 | 0.03-2† | Micafungin, caspofungin, azoles |
a
All patients were treated with caspofungin, with the exception of those in the study of Laverdiere et al. (126) (micafungin).
b
Symbols: *, caspofungin MICs; †, micafungin MICs.